Search Results

SonoVascular, Inc. has executed an exclusive clinical supply agreement with Lantheus Holdings, Inc. to use Lantheus’ microbubbles in combination with SonoVascular’s SonoThrombectomy System to treat deep vein thrombosis and pulmonary embolism.

Lantheus Holdings, Inc. announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer and Jean-Claude Provost, MD has been named Chief Science Officer, effective May 28, 2024.

Lantheus Holdings, Inc. today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177 Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT).

Radiopharm Theranostics Limited, a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company, and its affiliates.

POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH).

Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging FTC Chair Lina Khan to block the merger if it violates antitrust laws.

After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.

While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.